



IMPACT REPORT AND ACCOUNTS 2023/24

Breast Cancer UK Ltd
Charity No. 1138866 | Company No. 7348408



TABLE OF CONTENTS

ABOUT BREAST CANCER UK	3-7
Our charitable objectives	5
Our guiding principles	5
Impact Report / A word from the Chair and CEO	6-7
OUR SCIENCE PROGRAMME	8-15
Breast Cancer UK's Grant Funding Programme	10-13
Breast Cancer Prevention Conference	14-15
OUR EDUCATION PROGRAMME	16-19
Prevention hub and education content	17-18
Plans for our educational programme	19
OUR ADVOCACY PROGRAMME	20-23
Advocacy and campaigning	21
Collaboration	22
Next Steps	22-23
OUR GENEROUS SUPPORTERS	24-28
Regular Giving (The B Well Club)	25
Community and Events Fundraising	26-27
In Memory Gifts and Legacies	28
Corporate Partnerships	
FINANCIAL REVIEW	29-32
Principal funding sources	30
Charitable Expenditure	30-31
Reserves policy	31-32
Results and closing position	32
STRUCTURE GOVERNANCE AND MANAGEMENT	33-37
Structure	34
Governance	34
Staff	35
Risk Management	35
Statement of public benefit	36
Statement of Trustees Responsibilities for the Year Ended 31 March 2024	37
FINANCIAL STATEMENTS	38-50

ABOUT BREAST CANCER UK

Around 55,500 women and 370 men in the UK are diagnosed with breast cancer every year and it is predicted that 1 in 7 women will get breast cancer at some point in their lives. Yet, at least 30% of breast cancers are preventable.

That means that around 17,000 cases of breast cancer could be prevented each year, saving countless lives, reducing suffering and reducing the cost to the NHS.

We believe there are many opportunities to reduce breast cancer rates in the UK potentially saving millions of lives as a result. We give practical advice on how people can reduce their risk of getting breast cancer by making simple changes in their lives.

A unique aspect of our work focuses on the role played by hormone disrupting chemicals in increasing the risk of breast cancer and we work with other organisations to make our voice heard on this issue.

We also fund research that we believe could be a game-changer in the field of breast cancer prevention.

Our mission is to prevent suffering caused by preventable breast cancers through funding research, supporting individual behavioural change and campaigning for effective public health and environmental protections.

We believe our work can have a significant impact on helping women and men reduce their risk of developing breast cancer.

**BREAST CANCER RATES
DOUBLED IN 50 YEARS
+24% SINCE 1996**

56,000 women diagnosed with breast cancer every year

**A WOMAN'S LIFETIME
RISK OF BREAST
CANCER IS 1 IN 7**


(for UK women born after 1960)



1996




TODAY



56,000

Women diagnosed
with breast cancer
each year in the UK



96%

of breast cancers appear in
women over 40

Breast cancer is the

most common

cancer in
the UK




400

Men diagnosed
with breast cancer
each year in the UK

1 in 7

Women will
develop breast
cancer at some
point in their lives.



30%

of breast cancer cases
can be prevented

17,000

Cases of breast cancer that could be
prevented each year

OUR CHARITABLE OBJECTIVES

WE EDUCATE AND RAISE AWARENESS OF THE PREVENTABLE RISK FACTORS FOR BREAST CANCER AND PROVIDE PRACTICAL INFORMATION TO HELP PEOPLE REDUCE THEIR RISK

WE CAMPAIGN FOR POLICIES THAT SUPPORT THE PREVENTION OF BREAST CANCER

WE SUPPORT SCIENTIFIC RESEARCH THAT HELPS TO UNDERSTAND AND ADDRESS THE PREVENTABLE RISK FACTORS FOR BREAST CANCER

OUR GUIDING PRINCIPLES:

- Breast Cancer UK believes prevention is possible: more can be done to prevent breast cancers by tackling lifestyle and environmental risk factors.
- We are evidence based: scientific evidence is at the heart of our work with sources clearly identified.
- We champion high environmental and ethical standards: partnering with companies and suppliers whose own ethical and environmental policies match these standards.
- We believe in the right to know: we want to empower people by giving them the information they need about the preventable risk factors for breast cancer, so they can make informed choices.
- We believe in collaboration: we will actively identify, seek and establish collaborations with other stakeholders (e.g. charities, think tanks, companies, government and scientific institutions) to ensure we are effective in delivering our goals.

WELCOME TO OUR 2023/24 IMPACT REPORT

A WORD FROM OUR CHAIR AND CEO

We are delighted to share our Impact Report and Accounts for the financial year 2023/24.

Our mission to make breast cancer prevention a reality is a great challenge that we believe can be achieved through directly appealing to and nurturing our supporters, collaborating with those who share our passion and determination and investing in high-quality research and education. This year we took strides towards reaching this ambition by strengthening our visibility through an expansion of our science-backed content and personalised advice, striving to match the needs of our supporters.

We saw demand swell for our prevention education as we empowered greater numbers of people to take prevention into their own hands with our prevention quiz. We reached a significant milestone this year in hosting our first Breast Cancer Prevention Conference, proudly partnering with Middlesex University. The conference ignited new conversations and debates between scientists and experts across the health and environmental prevention research sectors, exploring the evidence, the gaps in our understanding and the priorities to act upon. We strengthened our scientific grant programme with a steady investment in new research grants and through new funding opportunities to cultivate greater interest and diversify this important field of research.

This year's achievements enabled us to edge closer to our strategic targets, to grow our scientific programme and investment, widen the impact of our education through significantly expanding access to our personalised prevention planners, empowering more people to make breast cancer prevention a part of their lives.

Our charity is entirely dependent on the generous donations of people, businesses, groups, clubs, schools, trust & foundations and associations who believe in and want to support our work. Our achievements would not have happened without their support. This year our growing number of supporters helped our charity sustain financial growth for the third year running enabling greater investments in our science and education. For this, we want to express our deepest gratitude and appreciation. We wholeheartedly thank all of our valued supporters.

Our engaged Board of Trustees oversaw the governance of our team and represented our charity with passion and commitment bringing a rich mix of skills and experiences. We were delighted to welcome Beezy Marsh who is an author and journalist, Nazia Tingay who is a Senior Payments Project Manager, Lotte Spencer who is a Marketing Director and Silvy Mardigian who is Head of Economics and Outcomes Research.

We were sad to say goodbye to Dr Britta Stordal, our Deputy Chair and Chair of our Science and Public Affairs Committee. Britta's investment in the charity and her skills, insights and passion have brought significant value to our cause. We thank her for her commitment. We also said goodbye to Nichole Taske, who also served on our Science and Public Affairs Committee bringing invaluable public health policy knowledge to the charity. We thank Nichole for her commitment. Finally, we farewelled Charlie Winstanley who also served on our Science and Public Affairs Committee, bringing a breadth of policy and public health knowledge. We thank him for his commitment.

Our passionate and talented team continued to expand to meet the swell in demand for our work. With this growth comes a greater mix of skills, backgrounds and experience enriching the work that we do. The team's tireless commitment to achieving impact is hugely appreciated. Their feedback has told us that they love working together to achieve one goal and that they feel their contribution is making a difference. We thank all of our colleagues for their commitment and dedication.

This year has shown that we can achieve our ambition and strive for more. As we enter the last year of our strategic plan we remain steadfast in our commitment to put breast cancer prevention at the core of the public health and environmental responses to this devastating disease. We look forward to continuing to stride forward with our supporters and partners to make preventing this disease a priority.



Ruth Freeborough
Chair, Breast Cancer UK



Thalie Martini
CEO, Breast Cancer UK

OUR SCIENCE PROGRAMME

Our objectives were to:

- Support high-quality, independent scientific research projects at universities or research institutes within the UK.
- Bring relevant, high-quality data and new research findings into the public arena
- Grow our scientific expertise and reputation in the field of breast cancer prevention

A key mission of ours is to understand the preventable causes of breast cancer so that we can translate this into practical measures that help reduce the impact of breast cancer on people's lives. Our science programme is dedicated to exploring the link between breast cancer and potentially harmful chemicals found in everyday products and in our environment. We have made this our focus as we believe that there is an urgent need to build greater evidence around the harms these chemicals may be causing to our health and our breast cancer risk.

While there is convincing evidence to show that lifestyle factors such as alcohol consumption and obesity can influence breast cancer risk, there is less wide-ranging evidence available on the effects of environmental chemicals and possible links with breast cancer.

Our grants programme aims to help fill the gap in our knowledge and understanding of this complex area of breast cancer risk.

BREAST CANCER UK'S GRANT FUNDING PROGRAMME

RESEARCH PROJECTS

Completed projects



Examining how Endocrine Disrupting Chemicals (EDCs) mixtures and a high-fat diet affect breast cancer

Dr Elisabete Silva, Brunel University

The project examined the impact of mixtures of Endocrine Disrupting Chemicals (EDCs) and saturated fats (that may result from a high fat diet) on early stages of breast cancer. Findings from this project showed that 3D spheroids of normal breast cells exposed to a mixture of Endocrine Disrupting Chemicals (EDCs) and saturated fats resulted in a more deformed structure compared to non-exposed cells. This project also validated an exciting new three-dimensional breast cancer model system known as "Breast-on-chip". This model contained three prominent cell types found in the breast and more closely resembled how breast cells behave in the body. The model will make future experiments involving mixtures of Endocrine Disrupting Chemicals (EDCs)/saturated fats more human-relevant.



Current Projects

Investigating effects of per- and poly-fluoroalkyl (PFAS, or per- and polyfluoroalkyl substances) substances on breast cancer development

February 2024 – Present

This PhD studentship project was awarded to Dr Mark Wade and PhD student Ms Lucie Bilton of the University of Hull. This project aims to investigate whether PFAS, or per- and polyfluoroalkyl substances ("forever chemicals") play a role in breast cancer development and determine whether microplastics that can leach PFAS, or per- and polyfluoroalkyl substances are found in breast tissue.

Normal breast cells will be exposed to PFAS, or per- and polyfluoroalkyl substances at levels found in the blood and then be assessed for characteristics often found in cancerous cells. The effect of long and short-term exposure will be analysed to see what changes occur immediately and which develop over time. Breast tissue from patients will also be analysed for microplastics.



Measurement of Endocrine Disrupting Chemicals (EDCs) in breast cancer **November 2023– Present**

This 18-month project was awarded to Dr Michael Antoniou with Research Assistant, Charlotte O'Hern, at King's College London. This project aims to assess the potential risks arising from Endocrine Disrupting Chemicals (EDCs) found in everyday products that can potentially lead to or promote breast cancer.

Frozen breast cancer samples will be screened for oestrogen-like chemical pollutants. Cancer and non-cancerous fatty tissue from the same breast will be analysed. The results will be used to assess if there is a connection between the amount and type of oestrogen-like chemical pollutants detected and breast cancer growth and spread.



Evaluating the effects of BPA on breast cancer development **February 2023 – Present**

This PhD studentship project was awarded to Prof Val Speirs and her PhD student Ms Katharina Kusserow at the University of Aberdeen. This project is investigating the effect of bisphenol A (BPA) on the non-cancerous breast and how it may contribute to breast cancer development.

The project will involve a systematic review of existing literature to assess the current understanding of how BPA affects breast tissue and computer-based approaches to identify genes related to BPA exposure. Laboratory experiments will then assess any potential involvement of those selected genes in breast cancer development. BPA levels will also be measured in blood samples donated by breast cancer patients.



Biomonitoring and molecular toxicity profiling of bisphenol mixtures **February 2022 – Present**

This PhD studentship was awarded to Dr Michael Antoniou and his PhD student Connor Powell at King's College London. This research project aims to complete a biomonitoring study where urine samples are collected from the general public and analysed for bisphenol compounds to help determine the levels of bisphenol exposure in the UK population.

Publications

Di Pasquale A. Endocrine Disrupting Chemicals: the role they play in breast cancer. Open Access Government. 2024.

<https://www.openaccessgovernment.org/endocrine-disrupting-chemicals-the-role-they-play-in-breast-cancer/174963/>

Powell C, Mesnage R, Antoniou MN, Vandenberg LN. Low dose effects of environmental chemicals: Bisphenol A as a case study. Encyclopedia of Toxicology, Fourth Edition: Volume 1-9 2024;5:955-67 <https://doi.org/10.1016/B978-0-12-824315-2.00762-4>

A NEW STRUCTURE FOR OUR GRANT APPLICATION ROUND 2023/24

Our most recent funding round called for applications that focus on the relationship between Endocrine Disrupting Chemicals (EDCs) and breast cancer risk; this was launched in November 2023 and closed in February 2024. For this funding round, we developed a new funding structure. This year two separate grants were available, known as our Foundation Award and Seed Award.

Our Foundation Award supports anchoring new principal investigators in the research area of breast cancer prevention. Applications were asked to focus on Endocrine Disrupting Chemicals (EDCs) (known or suspected) and breast cancer risk. The Award will fund up to £150,000; primary applicants should be within 12 years of their PhD being awarded. Alongside the proposed funding for research, Breast Cancer UK also offered an optional career coaching programme for the duration of the grant to help support and develop the wider skills of the early career scientist.

Our Seed Award is focused on chemicals and breast cancer risk. Funding can be applied flexibly and may be utilised as a top-up for a project close to completion, to obtain a specific piece of equipment, or to fund a pilot project focused on chemicals and breast cancer risk. The Seed Award is limited to a total cost of £25,000.

Funding decisions will be finalised early summer 2024.



Independent Scientific Review panel

Breast Cancer UK's Independent Scientific Review Panel provides vital expertise and scrutiny to our growing grant programme and strengthens our communicable science. The Panel, currently comprised of 14 expert members, are all independent scientists or clinicians who have knowledge across the breadth of breast cancer prevention. As well as providing peer review assessments in our grant programme, the Panel is also consulted for our in-house authored science reviews, which is critical for our Patient Information Forum Accreditation.

Health Information

Our health information continues to strengthen through the publishing of several major new documents (published onto our website and linked), including our Fibre, the Gut Microbiome & Breast Cancer; Critical Windows of Susceptibility for Breast Development; PFAS, or per- and polyfluoroalkyl substances and Breast Cancer and HRT, Menopause and Breast Cancer scientific reviews.

As part of our continued development of accessible health education content, we introduced health information on Life Stages, which incorporate Key Fact Sheets based on the Unborn Baby and Breast Cancer Risk; Pregnancy and Breast Cancer Risk; Breastfeeding; Newborn and Childhood; Puberty and Breast Cancer Risk and Menopause and Breast Cancer Risk. These new resources follow the life course and are intended to communicate how being at different stages of life can affect our breast cancer risk as well as our susceptibility to Endocrine Disrupting Chemicals.

In addition to our Life Stages resource, we overhauled the Chemicals pages of our Reduce Your Risk section and introduced key fact sheets offering an accessible summary to our latest scientific reviews. These new fact sheets include Parabens and breast cancer, PFAS, or per- and polyfluoroalkyl substances and breast cancer as well as a resource describing what the endocrine system is and how Endocrine Disrupting Chemicals can affect our health.

We attended the London Maternity and Midwifery Festival in February 2024, which saw high engagement with our science content, both through our leaflet-based information at our stand, and our oral presentation discussing foetal and maternal exposures to Endocrine Disrupting Chemicals. Almost 350 health professionals attended the Festival, with many taking resources from our stand to their own clinical settings.

Association of Medical Research Charities Membership

In January 2024, we received notification that our application to join the Association of Medical Research Charities (AMRC) was successful. The AMRC supports medical research charities to enhance real-world impact through research and innovation. The organisation ensures that member charities fund the highest quality research through developing guides, training and carrying out regular audits. We were delighted to be accepted as Introductory members to the organisation, which reflects and bolsters our dedication to supporting excellent world-leading research, and are now working towards Full membership.

BREAST CANCER PREVENTION CONFERENCE

On the 21st-22nd June 2023, we held our inaugural Breast Cancer Prevention Conference at Middlesex University. The aim of the conference was to bring together scientists, clinicians, students and members of other charities to collectively acknowledge, debate and discuss the latest developments in breast cancer prevention.

The conference combined two critical themes of breast cancer prevention: the risks posed by environmental chemicals and how lifestyle choices can affect breast cancer risk.

Over two absorbing days, world-leading clinicians, scientists, and researchers from as far afield as the US, Sweden and Switzerland discussed and debated the latest research and science around breast cancer risk factors.

The conference's climax was the panel discussion, consisting of four leading scientists and clinicians. The discussion saw a robust debate on taking the science forward to ensure it meets the criteria needed to drive regulatory and political change.

Feedback from conference attendees was overwhelmingly positive, with delegates praising all aspects of the conference from the speaker line-ups and quality of the talks to the venue and organisation. Furthermore, 100% of delegates who filled in the feedback form said they were 'very likely' to attend any future conferences held by Breast Cancer UK.

Public engagement on social media was also high across the two days with many positive posts on the conference.

To read our 2023 conference report and view our conference video, please click [here](#).

PLANS FOR THE SCIENCE PROGRAMME

With the success of our last conference, we are aiming to host this as a biannual event, with the next conference due in June 2025.

We intend for the focus of the event to be breast cancer primary prevention, encompassing both lifestyle and environmental factors. We seek to continue to provide a platform for scientists to come together, network, discuss and celebrate the latest high-quality prevention research from across the globe.

Our grants programme continues to grow, and we anticipate opening a new grant funding round in autumn 2024, with closing in early spring.

The focus of the funding will remain on Endocrine Disrupting Chemicals (EDCs) and breast cancer risk and will mirror the structure of the previous 2023/2024 funding round.

Our science reviews continue to consolidate our understanding of breast cancer risk factors and help to deliver educational information to the public through the creation of daughter documents including key fact sheets, blogs and videos. We plan to deliver science reviews focussed on several key and emerging risk areas including phthalates; the microbiome and parabens.



OUR EDUCATION PROGRAMME

Our objectives were to:

- Develop educational advice for members of the public who want to know more about lifestyle and environmental risk factors for breast cancer
- Improve access to practical solutions that help people take direct action to reduce their risk
- Reach and engage more young women with our message
- Grow and consolidate our ambassador programme so that we help more people understand how to reduce their risk.

PERSONALISED PREVENTION AND EDUCATION

Our personalised approach to supporting individual prevention gained ground this year through the growth and continued improvement of our quiz and supporting interactive digital resources. More people than ever took our quiz and many are reporting back on their progress in maintaining the changes that they have put in place to reduce their risk. Our plans for the future are to continue to scale this up working closely with community and health partners to promote our practical advice.

PREVENTION HUB AND EDUCATION CONTENT

There were over 71,000 users of the Prevention Hub this year, almost double that of the prior year and over 3 times the Hub's 3-year target. Over 36,000 people used the Chemicals iGuide; over 12,000 used the Everyday iGuide and over 15,000 used the Quiz.

About 1900 new people made a prevention plan and signed up to receive our monthly Prevention Pulse magazine. This is over 4 times higher than the prior year, thanks to additional promotion of the Quiz around Prevention Week, in June and Breast Cancer Awareness Month, in October, plus the Quiz being made more prominent on the website and being featured in all our outreach events and education materials.



1900

Pulse sign ups



12,000

Everyday
iGuide



15,000

Taken the
quiz



36,000

Chemical
iGuide



71,000

Hub users

A new version of the Quiz was also launched at the end of Breast Cancer Awareness Month. The new version captures more details about Quiz takers, such as their age, ethnicity and gender identity and this shows that the Quiz is attracting a very good representation of the UK population, by age, region and ethnicity.

The new Quiz also offers people additional tailored email support for 6 months, if they want to drink less alcohol, or get more active, to reduce their risk of breast cancer. Over 300 people chose extra support to drink less alcohol and about 350 people chose extra support to be more active.

People are also now being encouraged to retake the Quiz at least six months apart, so that the impacts of adopting reduce your risk advice and activities can be better assessed. Over 660 people retook the Quiz this year and over 200 of them did this at least 6 months apart.

PREVENTION TALKS, INSIGHTS AND FEEDBACK

Demand for our education talks increased significantly this year. To support this demand and to enable wider access to our life changing prevention education, we will develop a scalable outreach education programme to take our talks and education to people across the country.

PREVENTION WEEK 2023

Age-related breast cancer risk:

During Prevention Week 2023, we focused on raising awareness of the significant increase in breast cancer risk among women over 40. Representing over 95% of new cases, this demographic highlights the importance of targeted prevention efforts.

To address this significant issue, we developed a comprehensive campaign to educate the public about the age-related factors contributing to breast cancer risk and empowering individuals to adopt proactive measures for risk reduction. By highlighting a different risk factor each day, we emphasised the creation of sustainable healthy habits as a cornerstone of prevention.

We introduced a downloadable Weekly Wellness Planner to support people adopt healthier lifestyles. This practical tool empowers users to track progress towards their health goals, such as increasing physical activity, reducing alcohol consumption, or improving nutrition.

BCAM 2023

Move More, Raise More, Reduce Risk:

Building upon the success of the previous year, our Breast Cancer Awareness Month campaign in 2023 once again highlighted the powerful link between physical activity and breast cancer prevention. Our signature 30-Day Challenge encouraged participants to incorporate daily exercise into their routines, fostering healthy habits while raising vital funds.

To further support our prevention community, we introduced the B Well Club, a membership programme dedicated to prevention. Members received exclusive wellness advice, recipes, and exercise tips to empower them to make lasting lifestyle changes.

By combining fundraising with education and support, we aimed to create a comprehensive approach to reducing breast cancer risk.

PLANS FOR OUR EDUCATIONAL PROGRAMME

Next year we plan to make our prevention education even more accessible through introducing a high quality education outreach programme to complement our digital offer. The Quiz will be integrated into the outreach programme and will continue to evolve with tailored email support for people who want to improve lifestyle risk factors for breast cancer.

By nurturing relationships with the many people who take the quiz, and analysing their responses, we will implement research measures to help us understand and evaluate the benefits our quiz and tailored education have in reducing people's risk over time. This will give us practical insights into the impact of our prevention work.

breast cancer uk. Prevention Hub 47,611 people taken the quiz

Prevention Saves Lives

Start your prevention journey with our quick quiz and planner.

Start Quiz >

"Love this... Really liked the prevention plan... Very helpful and important for me and raising my two tiny humans."

Choose prevention...

Take the right steps now to prevent breast cancer in the future.

Everyone has some risk of getting breast cancer, but there are easy everyday ways to help reduce your risk and be healthier all round.

Reduce Your Risk of Breast Cancer... our top tips

Watch on YouTube

OUR ADVOCACY PROGRAMME

Our objectives for the last year were to:

- Encourage a preventative approach by campaigning to improve legislation and public health policy which helps to promote the primary prevention of breast cancer.
- Work at UK levels for policy and regulatory changes that help to protect against breast cancer.
- Raise the profile of our key messages amongst political decision makers by establishing a network of activists to help us make our message heard.

OUR CAMPAIGNING

Our campaigning objectives remained consistent into our 23/24 year with a main focus on;

- Promoting preventative approaches to breast cancer and more broadly prevention being put at the centre of healthcare policy.
- Work to bring about policy changes at all levels of government that promote a preventative approach in health policy. Principally, the scrapping of the proposed Major Conditions Strategy and the return of a standalone Cancer Strategy.
- Advocate for a precautionary principle approach in chemicals regulation and the publication of a Chemicals Strategy.

We put our case to top officials in the Department for Environment Food and Rural Affairs. In collaboration with other organisations, we advocated to the Government to keep high regulatory standards and not diverge from the European Union's established regulatory system and EU REACH.

In preparation for the expected general election, we reached out to those in opposition and identified key alignments in our policy priorities on cancer prevention. We were proud to produce our first Manifesto for Breast Cancer Prevention, merging our scientific knowledge with our policy expertise on breast cancer prevention into a single document. Work on this began in the period covered by this report.

ADVOCACY AND CAMPAIGNING

This year we led on a number of consultation submissions including on the Regulatory Management Options Analysis for bisphenols where we highlighted the need for a greater focus on the cocktail effect on human health through exposure to multiple chemicals in our daily lives. While we continued to point out to the Government that the UK is falling well behind European countries such as Germany who continue to pursue more stringent restrictions on the use and distribution of bisphenols, it was frustratingly clear that the then Government was not persuaded on the urgency to address either point.

Given the limited progress with the Government's regulatory and policy developments on chemical exposures, thanks to the support of the Savitri Trustee, we collaborated with our partners in the NGO working group on hazardous chemicals to develop a bespoke public awareness campaign on the impact of harmful chemicals on our health including on our breast cancer risk. This work will feed into Breast Cancer UK's mobilisation campaign.

We continued to develop constructive relationships with the Department for Environment Food and Rural Affairs (Defra) and the Department for Health and Social Care (DHSC). We also engaged directly with Dr Philippa Whitford, then MP and breast cancer surgeon and the then MP for Hitchin and Harpenden, Bim Afolami who provided a message of support at our breast cancer prevention conference and also supported our cause by sharing our quiz with his constituents. Additionally, we wrote to;

- Victoria Atkins MP (then Secretary of State for Health and Social Care)
- Rishi Sunak MP (the Prime Minister)
- Steve Barclay (then Secretary of State for Health and Social Care)
- Rebecca Pow (then Parliamentary Under-Secretary of State at the Department for Environment, Food and Rural Affairs, with responsibility for chemicals policy)

COLLABORATION

Our size as an organisation, the complexity of the policy areas that we work within and the difficult political landscape that characterised this period made collaboration an absolutely crucial part of our work. We continue to be a driving force behind the NGO working group for hazardous chemicals which brings together several organisations with interests in chemical regulation. A sub-group was formed from this, the 'Health sub-committee', which looks specifically at the human health implications of exposure to harmful chemicals.

In addition, we have strong links with the EDC-Free Europe coalition and the European Movement with whom we share information and ideas around alignment with EU REACH (the European Regulatory System for Chemicals).

We have also continued to build alliances with organisations with whom we share policy priorities including CHEMTrust, Animal Free Research, the Women's Environmental Network, the Wildlife and Countryside Links and the Alcohol Health Alliance.

NEXT STEPS

Our priority looking ahead is to launch our manifesto alongside the general election, giving us a basis from which to influence policy development on breast cancer prevention. We will target key MPs, Peers and policy-makers who we believe should be engaging with our work.

We will continue to nurture our existing partnerships and recognise that these are vital in making sure that we are around the table for key policy discussions. However, we also recognise that there are other organisations, particularly health charities, who may be campaigning for similar outcomes to ourselves, such as improving the public's eating, drinking or buying habits and we will be actively looking to partner with those organisations.

As we come towards the end of the existing Public Affairs Strategy, we will embark on new planning work to set out a robust 3-year plan for our advocacy and campaigning work in the years ahead. We will be looking to build a plan that engages more closely with our supporters, empowering them to help drive the change needed to make breast cancer prevention a policy priority.




**OUR
GENEROUS
SUPPORTERS**

This was a year of continued growth for our fundraising team. A year in which we set the foundations for our long-term ambitions. An ambition to take our income from just over £1M to over £4M within the next 5 years. Backed by an army of committed supporters who are joining our mission to put prevention at the top of the breast cancer debate. We thank them all for their invaluable support.

REGULAR GIVING (THE B WELL CLUB)

We developed and launched our new monthly regular giving offer - The B Well Club. Each month we send our wonderful members fun and practical wellness advice backed by science.

We have curated recipes, exercises, healthy habits and much more to help people make small changes to their daily lives to improve their overall health and reduce their breast cancer risk.



COMMUNITY AND EVENTS FUNDRAISING

People fundraising for us has long been the bedrock of our fundraising programme and we're so grateful and thankful for their fantastic ongoing support.

This year 622 people ran events for us raising £480,504.84 an average of £772 per fundraiser. Alongside this several supporters took part in organised events to support our work this included:

- Battle Cancer: We had 42 participants who raised £22,092.24
- Kilt walk: We had 44 participants who raised £14,388.75
- Skydiving: We had 24 participants who raised £33,990.49.

HERE'S SOME HIGHLIGHTS FROM OUR WONDERFUL FUNDRAISERS:

- Thank you to Ivan Mond, a 90-year-old skydiver and his family who raised £8,576. We ensured they had impactful media coverage during April 2023 [here](#).
- Thank you to Ashley and Oliver from Northamptonshire who trekked to Everest Base Camp in August 2023, before attempting to climb and summit a nearby peak - Imja Tse (6,160m, 20,200 ft). They raised £5,916.63 [here](#).
- Thank you to brothers Alex and Olly from Derbyshire who took part in the Peak District Ultra Marathon at the start of October 2023 as their mum had recently been diagnosed with breast cancer, they raised £7,187 [here](#).
- Thank you to James Roden and his colleagues from the RAF Lechlade who took part in a pedalo challenge along the Thames in July 2023 and raised £14,041.26 [here](#).
- Thank you to Jessica Allan from the West Midlands and her sister Emma who organised a 20-mile sponsored walk at the end of March 2023 to mark 20 years since their mum Helen Brayn passed away, they raised £5,088.75 including gift aid on JustGiving [here](#).
- We thank Karen Whitehead who, in June 2023, shaved her head in solidarity with a friend who is currently going through breast cancer, raising £7,196 [here](#).
- Thank you to Nick White and his team TMAAT (Three Men and a Tent) who raised £6,283 as they took part in a cycling challenge from London to Athens in May and June 2023 [here](#).
- We thank Peter Mackenzie from Cheshire who, in August 2023, took on his second challenge for Breast Cancer UK. He played 250 holes of golf in 24 hours and raised £12,712.15 [here](#).
- Thank you to James Saunderson and 5 teams from The Unit Gym and Fitness who took part in Battle Cancer Scotland in June 2023. James's wife Hazel was being treated for Breast cancer. The group raised £15,052.78 [here](#).

- Thank you to Gavin O'Rourke from London who took part in the London Marathon in April 2023, his wife has previously had breast cancer. He raised £5,012.13 [here](#).
- Thank you to Hannah Blaber and friends from Knowle Tennis Club in Bristol who held a 12-hour Tennis Marathon in May 2023 in memory of their friend Malgo. They raised £5,500.47 [here](#).



PHILANTHROPIC GIVING

We are hugely grateful to those supporters who generously pledged their gifts through Wills and donated in memory of a loved one. These gifts have enabled us to make significant investments in our scientific research and our education programmes both of which have grown thanks to the highly valuable support of these donors.

Our two largest legacy gifts were from Mr Deryck Anthony Nott and from Mrs Jean Mary Hastings.

We plan to continue to nurture and develop rewarding relationships with donors whose dedication to our mission and our cause is key to strengthening and growing our impact.

We wholeheartedly thank all of our valuable donors for choosing to support our charity. We were extremely thankful to receive a number of other large in memory gifts from Mary Edkins, Amanda Symes and Ailsa Thomas.

CORPORATE PARTNERSHIPS

We were supported by a wide range of wonderful businesses and their great teams who do amazing things for us, from putting on golf days, throwing themselves out of planes, to donating a percentage of profits from the sale of products. We want to thank all of the businesses and organisations who generously supported us this year. Some highlights:

- Climbers Against Cancer raised £6,747 in total from October to December.
- We received £15,000 from Morelli Group Ltd who enjoyed a golf day organised by the staff at Morelli Group in memory of one of the employee's sisters - This was our biggest staff fundraising total from one event last year.
- For the second year in a row, the staff at Olayan Group raised just under £10,000 from their fundraising run for Breast Cancer UK.

Our plan for the future is to continue to build long-term business support from companies and organisations that share our values and passion for our cause.



FINANCIAL REVIEW

The Directors present their report with financial statements of the Company for the year ended 31st March 2024. In preparing this report the Directors have taken advantage of some of the special exemptions applicable to small companies.

PRINCIPAL FUNDING SOURCES

Total funds raised this year were £1,537,624 and saw income from donations (excluding legacy gifts) growing by 33% on last year (£1,143,570 up from £859,247). Total funds shows a generally sustained income generation compared to last year's total funds raised of £1,585,839. This demonstrates the continuing steady returns of our effort to grow the profile and outputs of our work. The team continued to manage risk through routine risk assessments and regular budget tracking and forecasting. Improving access to our messaging and education to wider and more diverse audiences continues to be our priority. We approached the development of our advice and awareness campaign through testing and learning from audience responses. We made a significant investment in relationship management systems which has enabled us to take a more informed and targeted approach to nurturing relationships with our supporters and audiences. The balance of effective risk management and innovation continues to drive the growth of our supporter community and the growth of our organisation.

Our largest source of income came from community fundraising £540,872 which was made up of individual fundraising £424,442, and fundraising by educational facilities, sports clubs and other clubs/societies £116,430. This was followed by income from legacy giving of £321,407. The next highest sources of income were from in memory giving £212,850, and individual giving £93,760.

We received £114,722 in fundraising from staff in corporate organisations. Finally, we continue to partner with smaller companies and individuals too and would particularly like to thank them for their ongoing support. Corporate donations including cause-related amounted to £62,159.

CHARITABLE EXPENDITURE

We continued to manage spending cautiously due to rising concerns relating to the cost-of-living crisis. We took steps to minimise costs and overheads while ensuring we maximised funds spent on our charitable cause. As with last year, we incorporated in our expenditure targets, strategic areas of investment to help progress our growth and impact in line with the objectives of our strategic plan.

We closely reviewed investments quarter by quarter and assessed risk, as part of investment decisions. This year, we spent 74% (855,555) on charitable activities and 26% (304,456) on raising funds.

Our most significant investment was in our scientific research programme (£397,909) followed by our education programme (£234,804) as we continued to increase activities to deliver accessible digital and print education content.

RESERVES POLICY

Purpose of the Reserves

The charity holds reserves to provide funding to support the continuation of the charitable aims and objectives and the ability to meet financial commitments in the event of a significant unforeseen reduction in income or increase in operational costs.

Level of Reserves

The level of reserves is set by considering the uncertain nature of the charity's income (which relies entirely on donations, legacies and grants) and the recurrent expenditure and financial commitments the charity has. The charity has limited overheads arising from accommodation as we do not have a central office space. Hence our main financial commitments and running costs arise from staffing and research grants.

Designated Funds

The charity is committed to funding research into the chemical and environmental causes of breast cancer. Research grant applications from independent academic institutions are considered periodically and approved at the Board level.

Designated funds represent funds approved by the Board for future spending on research grants and other projects that aim to deliver our charitable objectives. The level of designated funds is updated throughout the year to reflect the amount of funds set aside for future projects until the funds are either committed to a project or a decision is made to un-designate them if a project does not go ahead.

Free Reserves

Breast Cancer UK is committed to a programme of activity that meets our charitable objectives. Given the uncertain nature of legacies, budgets are prepared on the assumption that only in cases where we have already been formally notified, are they included in income.

As a result, sudden large legacies or donations that are received during the financial year can result in reserves being held that are more than Breast Cancer UK's reserves policy (free reserves) after allowing for designated funds.

To help us address this, our business plans now include a priority list of research and education projects which align with our strategic priorities and the impact that we want to achieve. Thus, excess legacies or unexpectedly large donations will be directed promptly to these projects. We are continuing to monitor legacy income for trends with a view to assessing the feasibility of including projections in future income target setting.

Authority, Monitoring and Reporting

Ongoing monitoring of the reserves is undertaken during the year by the CEO, Finance Director and Finance Trustee. We report the reserve position including how funds are allocated to the Audit Risk and Resources Committee.

Reserve Policy Review

The Reserves Policy is reviewed annually by the Audit, Risk and Resources Committee in February and approved by the Board of Trustees in March, reviewing in detail the reserve position and taking into account prevailing conditions in the charity sector and short-term and medium-term plans for the charity.

At the Board meeting on 27th March 2024, the Trustees determined that £313,940 should be held in emergency reserve. This represents 70% of our most vulnerable income stream and was calculated based on risk in the reduction of income in those income streams. The total reserve level is sufficient to allow for the financial implications of a downturn in income or the need to significantly increase operational expenditure.

General unrestricted funds at year-end were £2,130,846 of which £712,782 were designated funds, including £172,380 for science grants, £200,000 for the Science Foundation Award, £36,000 for the Breast Cancer Prevention Conference and £304,402 for other charity projects. Net of designated funds and our emergency reserve of £313,940, excess free reserves were £1,055,199

We were pleased to find that the negative impact on income from the cost-of-living crisis and the war in Ukraine did not occur this year, with steady income growth occurring throughout the year. Despite this, we recognise the continued uncertainty and have therefore maintained a precautionary approach to ensure we can weather the storm of any financial crisis ahead.

RESULTS AND CLOSING POSITION

The charity's income exceeded expenditure this year by £377,613. This surplus was welcome given the continuing investments we have made to grow our science and education programmes this year. Our total income reduced by £33,661 from 2023. Our total expenditure was 4% under budget. Total income exceeded our annual budget target by £709,664 including legacy and grants. In light of the ongoing cost of living crisis, we took a cautious approach to our target setting whilst increasing our outputs and contents. This along with some generous unexpected legacy gifts will explain the excess in income over targets.

Given our initial projection of £426,835 in planned deficit at 2023/24-year end, our very positive closing is a testament to our investment and risk management policy, yielding extremely favourable returns and stability for our charity. We enter the year ahead with confidence to stay on track to grow sustainably and achieve impact for our beneficiaries.

STRUCTURE GOVERNANCE AND MANAGEMENT

STRUCTURE

Breast Cancer UK is a charitable company limited by guarantee (registration number 07348408), registered on the 8th of November 2010 and registered as a charity on the 15th of August 2001 (registered charity number 1138866). The company was established under the Memorandum of Association, which established the objects and powers of the charitable company. In the event of the company being wound up, members are required to contribute an amount not exceeding £10.

Our charitable objectives are as follows:

1. to advance health and save lives by encouraging a preventative approach to breast cancer
2. to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk; and
3. to support scientific research that helps us to understand and address the preventable risk factors for breast cancer.


GOVERNANCE

The Directors of the Company, who are listed on the last page of this report are also charity trustees for the purposes of charity law and under the Company's articles are known as members of the Board of Trustees.

All members of the Board of Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 3 to the accounts. Several trustees have suffered from breast cancer or are close to people who have suffered from the disease. They use their own experience in this area to assist the charity.

In recruiting Trustees, the members seek to ensure the charity benefits from a broad range of different skills and expertise. Skills and expertise represented on the board include science and policy, medicine, cancer services, governance, law, accountancy, fundraising, PR, business management and IT. In the event of skills or individuals being lost due to retirements or resignations, the charity advertises for specific skills and interviews are carried out to ensure the most appropriate appointments are made.


This year we were sad to say goodbye to Britta Stordal, Nichole Taske and Charlie Winstanley. Britta Stordal who served as Deputy Chair stood down at the end of her second term on 23rd of September 2024. Nichole who had served as Trustee since 11 December 2019, stood down on 19th September 2024 and Charlie who served as Trustee since 30 June 2022 stood down on 5th June 2024. Both Nichole and Charlie resigned due to increasing work commitments. We were delighted to welcome four new Trustees to the board, Nazia Tingay, Lotte Spencer, Silvy Mardiguian and Beezy Marsh who each who joined the board on 11th March 2024.



STAFF

Breast Cancer UK's staff are our greatest asset and we are committed to supporting every employee to achieve their potential and achieve personal goals which in turn will assist the organisation to achieve its objectives. Since 2020 and in an effort to remain competitive, retain staff and attract talent, we have continuously reviewed and evolved the team's functions, structure, benefits and remuneration. This year we continued to expand our team across work areas to reinforce resourcing and expertise. We conduct regular reviews of our salaries and benefits package and we periodically consult with colleagues on work conditions, ways of working and personal satisfaction to inform the continued evolution of our unique organisational culture and values.

BREAST CANCER UK ORGANOGRAM



RISK MANAGEMENT

A risk register is established. Risk management sits with the CEO and ownership sits with specific Committees and the Board. The Committees of the Board of Trustees and the Board itself reviews the Risk Register at each meeting and it is updated regularly. Mitigating actions are considered and reviewed regularly. All policies and processes are under rolling review to ensure we are compliant with regulation.

STATEMENT OF PUBLIC BENEFIT


The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have regard to the Charity Commission's General Guidance on public benefit.

Our charitable objectives are enshrined in our Memorandum of Association and Trustees to ensure that the charity's activities are carried out for the public benefit. In July, these articles were formally amended with a special resolution passed to amend our 'objects' clause through our three new strategic approaches:

- to advance health and save lives by encouraging a preventative approach to breast cancer
- to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk
- to support scientific research that helps us to understand and address the preventable risk factors for breast cancer.

This report allows us to show how our charitable funds are spent and the impact that this has on those who access our information or use our services, as well as on the wider challenge to reduce breast cancer incidence rates.

By Order of the Board

A handwritten signature in dark ink, reading "Ruth Freeborough", is written on a piece of light-colored, slightly textured paper.

Ruth Freeborough (Chair and Director of the Board of Trustees)

Breast Cancer UK Limited

STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR ENDED 31 MARCH 2024

The trustees (who are also the directors of Breast Cancer UK Limited for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charity SORP
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is
- inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

FINANCIAL STATEMENTS

Breast Cancer UK Limited
Statement of financial activities (incorporating an income and expenditure account)
For the year ended 31 March 2024

	Note	2024			2023		
		Unrestricted Fund	Restricted Fund	Total Fund	Unrestricted Fund	Restricted Fund	Total Fund
		£	£	£	£	£	£
Income from:							
Donations and legacies	2	1,443,859	21,118	1,464,977	1,433,844	137,441	1,571,285
Charitable activities	3	-	-	-	83	-	83
Investments	4	72,647	-	72,647	14,471	-	14,471
Total income		1,516,506	21,118	1,537,624	1,448,398	137,441	1,585,839
Expenditure on:							
Raising funds	5	304,456	-	304,456	205,476	-	205,476
Charitable activities	5						
Campaign costs		220,392	2,450	222,842	141,996	22,550	164,546
Education costs		213,672	21,132	234,804	185,993	18,480	204,473
Science costs		297,909	100,000	397,909	137,235	-	137,235
Total expenditure		1,036,429	123,582	1,160,011	670,700	41,030	711,730
Net income / (expenditure) for the year	6	480,077	(102,464)	377,613	777,698	96,411	874,109
Transfers between funds		-	-	-	2,994	(2,994)	-
Net income / (expenditure) before other recognised gains and losses		480,077	(102,464)	377,613	780,692	93,417	874,109
Net movement in funds		480,077	(102,464)	377,613	780,692	93,417	874,109
Reconciliation of funds:							
Total funds brought forward		1,601,844	151,389	1,753,233	821,152	57,972	879,124
Total funds carried forward		2,081,921	48,925	2,130,846	1,601,844	151,389	1,753,233

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note to the financial statements.

Breast Cancer UK Limited
Balance sheet

As at 31 March 2024


Company no. 07348408

	Note	£	2024 £	2023 £
Current assets:				
Debtors	10	191,082	38,746	
Cash at bank and in hand		2,251,559	1,932,025	
		<u>2,442,641</u>	<u>1,970,771</u>	
Liabilities:				
Creditors: amounts falling due within one year	12	(185,371)	(109,110)	
Net current assets / (liabilities)			<u>2,257,270</u>	<u>1,861,661</u>
Total assets less current liabilities			2,257,270	1,861,661
Creditors: amounts falling due after one year	13		<u>(126,424)</u>	<u>(108,428)</u>
Total net assets / (liabilities)			<u>2,130,846</u>	<u>1,753,233</u>
The funds of the charity:	17			
Restricted income funds			48,925	151,389
Unrestricted income funds:				
Designated funds		712,782	444,000	
General funds		<u>1,369,139</u>	<u>1,157,844</u>	
Total unrestricted funds			<u>2,081,921</u>	<u>1,601,844</u>
Total charity funds			<u>2,130,846</u>	<u>1,753,233</u>

The financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

02/12/24

Approved by the trustees on and signed on their behalf by



Ruth Freeborough
Trustee

Breast Cancer UK Limited
Statement of cash flows

For the year ended 31 March 2024

	Note	2024 £	£	2023 £	£
Cash flows from operating activities					
Net cash provided by / (used in) operating activities	18	246,887		769,964	
Investing activities					
Investment income received		<u>72,647</u>		<u>14,471</u>	
Net cash generated from investing activities		72,647		14,471	
Net cash provided by / (used in) financing activities		<u>-</u>		<u>-</u>	
Change in cash and cash equivalents in the year		319,534		784,435	
Cash and cash equivalents at the beginning of the year		<u>1,932,025</u>		<u>1,147,590</u>	
Cash and cash equivalents at the end of the year	19	<u><u>2,251,559</u></u>		<u><u>1,932,025</u></u>	

1 Accounting policies

Charity information

Breast Cancer UK Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is, The Union Building, 51–59 Rose Lane, Norwich, Norfolk, NR1 1BY, England.

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102 – effective 1 January 2019) – (Charities SORP FRS 102) and the Companies Act 2006.

The charitable company meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

b) Going concern

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern. The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

d) Donations of gifts, services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees' annual report for more information about their

On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

e) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

f) Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

1 Accounting policies (continued)

g) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

- Costs of raising funds relate to the costs incurred by the charitable company in inducing third parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising purpose
- Expenditure on charitable activities includes the costs of delivering services, undertaken to further the purposes of the charity and their associated support costs.
- Other expenditure represents those items not falling into any other heading

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

h) Allocation of support costs

Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the basis which are an estimate, based on staff cost, of the amount attributable to each activity.

Where information about the aims, objectives and projects of the charity is provided to potential beneficiaries, the costs associated with this publicity are allocated to charitable expenditure.

i) Operating leases

Rental charges are charged on a straight line basis over the term of the lease.

j) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life.

k) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash balances exclude any funds held on behalf of service users.

m) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

o) Pensions

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Income from donations and legacies

	Unrestricted £	Restricted £	2024 Total £	Unrestricted £	Restricted £	2023 Total £
Donations and gifts	1,122,452	21,118	1,143,570	776,806	82,441	859,247
Legacies receivable	321,407	-	321,407	657,038	-	657,038
Grants	-	-	-	-	55,000	55,000
	<u>1,443,859</u>	<u>21,118</u>	<u>1,464,977</u>	<u>1,433,844</u>	<u>137,441</u>	<u>1,571,285</u>

3 Income from charitable activities

	Unrestricted £	Restricted £	2024 Total £	Unrestricted £	Restricted £	2023 Total £
Ticket sales	-	-	-	83	-	83
Total income from charitable	<u>-</u>	<u>-</u>	<u>-</u>	<u>83</u>	<u>-</u>	<u>83</u>

4 Income from investments

	Unrestricted £	Restricted £	2024 Total £	Unrestricted £	Restricted £	2023 Total £
Deposit account interest	72,647	-	72,647	14,471	-	14,471
	<u>72,647</u>	<u>-</u>	<u>72,647</u>	<u>14,471</u>	<u>-</u>	<u>14,471</u>

5 Analysis of expenditure

	Cost of raising funds	Campaign costs	Charitable activities			2024 Total	2023 Total
	£	£	Education costs	Science costs	Support costs	£	£
Staff costs (Note 7)	150,260	145,839	139,840	108,015	129,428	673,382	462,695
Consultancy fees	13,501	-	16,758	3,798	5,146	39,203	24,365
Promotional activities	31,032	2,760	6,948	33,949	-	74,689	29,949
Subscriptions and memberships	1,234	3,384	1,141	-	1,041	6,800	16,205
Training costs	1,340	20	2,242	65	8,689	12,356	4,077
Grants	-	-	-	199,272	-	199,272	1,039
Recruitment costs	1,560	2,003	321	3,103	926	7,913	9,666
Prevention hub	-	-	-	-	-	-	204
Kick Start a Chemicals	-	-	-	-	-	-	22,550
Breast Cancer in Men	-	-	1,330	-	-	1,330	18,480
Donor entry and platform fees	34,968	-	-	-	-	34,968	19,191
Staff welfare	-	-	-	-	6,135	6,135	5,000
Travel, accommodation and meetings	932	3,008	3,103	951	16,997	24,991	12,771
Insurance	-	-	-	-	534	534	2,066
Website and IT	-	-	-	-	53,658	53,658	58,946
Printing, postage and stationery	1,804	-	-	-	608	2,412	2,881
Sundries	-	-	-	-	2,647	2,647	2,712
Telephone	-	-	-	-	3,240	3,240	3,768
Governance costs	-	-	-	-	-	-	110
Bank charges	-	-	-	-	49	49	-
Audit fees	-	-	-	-	7,200	7,200	6,600
Accountancy Fees	-	-	-	-	2,592	2,592	5,354
Legal and professional fees	-	-	-	-	4,580	4,580	2,213
Trustees' meetings and training	-	-	-	-	2,060	2,060	888
	236,631	157,014	171,683	349,153	245,530	1,160,011	711,730
Support costs	63,272	61,410	58,884	45,483	(229,049)	-	-
Governance costs	4,553	4,418	4,237	3,273	(16,481)	-	-
Total expenditure 2024	304,456	222,842	234,804	397,909	-	1,160,011	-

The total expenditure £1,036,429 was unrestricted (2023: £670,700) and £123,582 (2023: £41,030) was restricted.

Analysis of expenditure (prior year)

	Cost of raising funds	Campaign costs	Charitable activities			2023 Total
	£	£	Education costs	Science costs	Support costs	£
Staff costs (Note 7)	109,442	82,415	104,867	84,032	81,939	462,695
Consultancy fees	600	596	16,781	600	5,788	24,365
Promotional activities	20,660	2,524	3,985	2,780	-	29,949
Subscriptions and memberships	2,286	9,211	1,074	-	3,634	16,205
Training costs	422	119	936	264	2,336	4,077
Grants	-	-	-	1,039	-	1,039
Recruitment costs	3,369	2,782	-	1,053	2,462	9,666
Prevention hub	-	96	108	-	-	204
Kick Start a Chemicals	-	22,550	-	-	-	22,550
Breast Cancer in Men	-	-	18,480	-	-	18,480
Donor entry and platform fees	19,191	-	-	-	-	19,191
Staff welfare	-	-	-	-	5,000	5,000
Travel, accommodation and meetings	1,569	2,371	620	860	7,351	12,771
Insurance	-	-	-	-	2,066	2,066
Website and IT	-	-	-	-	58,946	58,946
Printing, postage and stationery	2,152	-	-	5	724	2,881
Sundries	-	-	-	-	2,712	2,712
Telephone	-	-	-	-	3,768	3,768
Finance costs	-	-	-	-	110	110
Governance costs	-	-	-	-	-	-
Audit fees	-	-	-	-	6,600	6,600
Accountancy Fees	-	-	-	-	5,354	5,354
Legal and professional fees	-	-	-	-	2,213	2,213
Trustees' meetings and training	-	-	-	-	888	888
	159,691	122,664	146,851	90,633	191,891	711,730
Support costs	42,021	38,119	53,858	42,838	(176,836)	-
Governance costs	3,764	3,763	3,764	3,764	(15,055)	-
Total expenditure 2023	205,476	164,546	204,473	137,235	-	711,730

For the year ended 31 March 2024

6 Net incoming resources for the year

This is stated after charging / crediting:

	2024 £	2023 £
Auditors' remuneration (excluding VAT): Audit	6,000	5,500

7 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Staff costs were as follows:

	2024 £	2023 £
Salaries and wages	579,127	419,754
Social security costs	44,300	29,517
Employer's contribution to defined pension schemes	20,010	13,424
Freelance staffs	29,945	-
	<u>673,382</u>	<u>462,695</u>

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2024 Number	2023 Number
£70,001 – £80,000	-	1
£80,001 – £90,000	1	-

The total employee benefits including pension and national insurance contributions of the key management personnel were £89,409 (2023: £79,596).

The charity trustees were not paid or received any other benefits from employment with the charity in the year (2023: £nil). No charity trustee received payment for professional or other services supplied to the charity (2023: £nil).

Trustees' expenses include the payment or reimbursement of travel and subsistence costs totalling £280 (2023: £197) relating to attendance at meetings of the trustees.

8 Staff numbers

The average monthly number of employees during the year was:

	2024 No.	2023 No.
Management and administration	4	3
Fundraising	3	3
Campaigns, Science and Education	8	8
	<u>15</u>	<u>14</u>

9 Related party transactions

There are no related party transactions to disclose for 2024 (2023: none).

There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties.

For the year ended 31 March 2024

10 Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

11 Debtors

	2024	2023
	£	£
Monies owed	17,204	12,183
Other debtors	9,546	24,889
Prepayments and accrued income	164,332	1,674
	<u>191,082</u>	<u>38,746</u>

12 Creditors: amounts falling due within one year

	2024	2023
	£	£
Trade creditors	20,401	15,414
Taxation and social security	12,975	-
Grants payable	139,514	83,769
Other creditors	3,345	-
Accruals	9,136	9,927
	<u>185,371</u>	<u>109,110</u>

13 Creditors: amounts falling due after one year

	2024	2023
	£	£
Grants payable (note 14)	126,424	108,428
	<u>126,424</u>	<u>108,428</u>

14 Grants payable

Grants payable included in the financial statements as follows:

	2024	2023
	£	£
Grants payable is included within:		
Current liabilities	139,514	83,769
Non-current liabilities	126,424	108,428
	<u>265,938</u>	<u>192,197</u>
Movements in the year:		
Balance at the beginning of the year	192,197	252,281
Released from previous periods	(125,532)	(60,084)
Amount accrued in the year	199,273	-
	<u>265,938</u>	<u>192,197</u>

15 Pension scheme

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £20,010 (2023 - £13,424).

For the year ended 31 March 2024

16 Analysis of net assets between funds

	General unrestricted £	Designated £	Restricted £	Total funds £
Net current assets	1,495,563	712,782	48,925	2,257,270
Long term liabilities	(126,424)			(126,424)
Net assets at the end of the year	1,369,139	712,782	48,925	2,130,846

17 Movements in funds

	At the start of the year £	Incoming resources & gains £	Outgoing resources & losses £	Transfers £	At the end of the year £
Restricted funds:					
Young people educational resource	47,570	-	-	-	47,570
Breast cancer in men resource	1,567	1,118	(1,330)	-	1,355
Bisphenols research project	19,802		(19,802)	-	-
Chemicals movement	2,450		(2,450)	-	-
General science research	80,000	20,000	(100,000)	-	-
Total restricted funds	151,389	21,118	(123,582)	-	48,925
Unrestricted funds:					
Designated funds:					
Science Grant Budget	420,000	-	(200,000)	(47,620)	172,380
Conversion of Online Quiz	10,000	-	(10,000)	-	-
HRT Scientific brief	9,000	-	(9,000)	-	-
Breast Feeding resource	5,000	-	(5,000)	-	-
BCUK Prevention Conference 2025	-	36,000	-	-	36,000
Outreach Programme	-	37,000	-	-	37,000
Science Foundation Award	-	200,000	-	-	200,000
Seed Awards	-	50,000	-	47,620	97,620
Reduce your Risk impact study	-	50,000	-	-	50,000
Development of supper clubs	-	23,400	-	-	23,400
Development of	-	24,317	-	-	24,317
Devolved parliaments outreach	-	5,000	-	-	5,000
Economic analysis tool	-	5,000	(5,000)	-	-
BCUK branding review	-	20,000	(11,800)	-	8,200
Mobilisation campaign	-	15,000	-	-	15,000
BCUK Podcast	-	20,365	(3,000)	-	17,365
BCUK Corporate film	-	10,000	-	-	10,000
Accessibility Audit	-	6,500	-	-	6,500
Website updates	-	10,000	-	-	10,000
Total designated funds	444,000	512,582	(243,800)	-	712,782
General funds	1,157,844	1,003,924	(792,629)	-	1,369,139
Total unrestricted funds	1,601,844	1,516,506	(1,036,429)	-	2,081,921
Total funds	1,753,233	1,537,624	(1,160,011)	-	2,130,846

For the year ended 31 March 2024

17. Movements in funds (Continued)

Purposes of restricted funds

Income, which is received for specific purposes, as – for example – grants and donations – is accounted for as restricted funds, with expenditure usually attributed over a specific period of time. The charity manages restricted funds carefully, keep expenditure under regular review, and aim to meet the specified purposes.

Purposes of designated funds

Designated funds are the funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

Movements in funds (prior year)

	Balance at 1 April 2022 £	Incoming resources & gains £	Outgoing resources & losses £	Transfers £	Balance at 31 March 2023 £
Restricted funds:					
Breast Density Research Project	2,994	-	-	(2,994)	-
Oxysterols Project	-	-	-	-	-
Creation and development of DLT	86	-	-	(86)	-
Young people educational resource	17,570	30,000	-	-	47,570
Breast cancer in men resource	17,570	2,391	(18,480)	86	1,567
Bisphenols research project	19,752	50	-	-	19,802
Chemicals movement	-	25,000	(22,550)	-	2,450
General science research	-	80,000	-	-	80,000
Total restricted funds	57,972	137,441	(41,030)	(2,994)	151,389
Unrestricted funds:					
Designated funds:					
Science Grant Budget	200,000	220,000	-	-	420,000
CRM Development	25,000	-	(25,000)	-	-
Conversion of Online Quiz	-	10,000	-	-	10,000
HRT Scientific brief	-	9,000	-	-	9,000
Breast Feeding resource	-	5,000	-	-	5,000
Total designated funds	225,000	244,000	(25,000)	-	444,000
General funds	596,152	1,204,398	(645,700)	2,994	1,157,844
Total unrestricted funds	821,152	1,448,398	(670,700)	2,994	1,601,844
Total funds	879,124	1,585,839	(711,730)	-	1,753,233

For the year ended 31 March 2024

18 Reconciliation of net income / (expenditure) to net cash flow from operating activities

	2024 £	2023 £
Net income / (expenditure) for the reporting period (as per the statement of financial activities)	377,613	874,109
Dividends, interest and rent from investments	(72,647)	(14,471)
(Increase)/decrease in debtors	(152,336)	(13,364)
Increase/(decrease) in creditors	94,257	(64,300)
Net cash provided by / (used in) operating activities	<u>246,887</u>	<u>781,974</u>

19 Analysis of cash and cash equivalents

	At 1 April 2023 £	Cash flows £	Other changes £	At 31 March 2024 £
Cash in hand	<u>1,932,025</u>	<u>319,534</u>	<u>-</u>	<u>2,251,559</u>
Total cash and cash equivalents	<u>1,932,025</u>	<u>319,534</u>	<u>-</u>	<u>2,251,559</u>

20 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

🌐 info@breastcanceruk.org.uk
✉ www.breastcanceruk.org.uk
🐦 @BreastCancer_UK
📷 @breastcanceruk
📘 facebook.com/breastcanceruk
🌐 linkedin.com/company/breast-cancer-uk
🏠 Breast Cancer UK (2019)
BM Box 7767
London
WC1N 3XX
Tel: 0845 6801322